Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000305

Drug Information
NameBetaxolol
SynonymsPrestwick1_000382; AC1L1DIZ; SPBio_002484; Lopac0_000193; CHEBI:3082; BSPBio_000563; CHEMBL423; DB00195; Betazolol; Prestwick3_000382; ALO-1401-02; D07526; Kerlone; L000125; Betaxolol (TN); (.+/-.)-1-[p-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol; 1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; SL 75212; CID2369; UNII-O0ZR1R6RZ2; 1-[(4-{2-[(cyclopropylmethyl)oxy]ethyl}phenyl)oxy]-3-[(1-methylethyl)amino]propan-2-ol; Prestwick0_000382; Betaxolol HCL; Prestwick2_000382; C06849; HMS2089I07; AC-1115; NCGC00024863-04; Betaxolol (INN); MolPort-003-845-027; 63659-18-7; LS-122005; 2-Propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-; C18H29NO3; 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; betaxolol; NCGC00024863-03; Betaxololum; 1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol; NCGC00015159-08; KERLEDEX; Betaxololum [INN-Latin]; Betaxolol [INN:BAN]; 1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol; BRD-A02759312-003-03-9; BPBio1_000621; SL-75212; 63659-19-8 (hydrochloride)
Trade NameBetoptic; Betoptic S; Lokren; Kerlone
CompanyLorex Pharmaceuticals
IndicationHypertension
[ICD9: 401   ICD10: I10, I11, I12, I13, I15]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-1
2-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3
InChIKeyNWIUTZDMDHAVTP-UHFFFAOYSA-N
Canonical SMILESCC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O    
Therapeutic ClassAntihypertensive Agents
CAS NumberCAS 63659-18-7
FormulaC18H29NO3
PubChem Compound IDCID 2369.
PubChem Substance IDSID 9067.
SuperDrug ATC IDC07AB05; S01ED02
SuperDrug CAS ID063659187;
TargetBeta-1 adrenergic receptorAntagonist[2][3]
Ref 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 2beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29. Epub 2009 Feb 12. To Reference
Ref 3Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists. Br J Pharmacol. 2000 Jun;130(4):759-66. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543